AGL 38.02 Increased By ▲ 0.08 (0.21%)
AIRLINK 197.36 Increased By ▲ 3.45 (1.78%)
BOP 9.54 Increased By ▲ 0.22 (2.36%)
CNERGY 5.91 Increased By ▲ 0.07 (1.2%)
DCL 8.82 Increased By ▲ 0.14 (1.61%)
DFML 35.74 Decreased By ▼ -0.72 (-1.97%)
DGKC 96.86 Increased By ▲ 4.32 (4.67%)
FCCL 35.25 Increased By ▲ 1.28 (3.77%)
FFBL 88.94 Increased By ▲ 6.64 (8.07%)
FFL 13.17 Increased By ▲ 0.42 (3.29%)
HUBC 127.55 Increased By ▲ 6.94 (5.75%)
HUMNL 13.50 Decreased By ▼ -0.10 (-0.74%)
KEL 5.32 Increased By ▲ 0.10 (1.92%)
KOSM 7.00 Increased By ▲ 0.48 (7.36%)
MLCF 44.70 Increased By ▲ 2.59 (6.15%)
NBP 61.42 Increased By ▲ 1.61 (2.69%)
OGDC 214.67 Increased By ▲ 3.50 (1.66%)
PAEL 38.79 Increased By ▲ 1.21 (3.22%)
PIBTL 8.25 Increased By ▲ 0.18 (2.23%)
PPL 193.08 Increased By ▲ 2.76 (1.45%)
PRL 38.66 Increased By ▲ 0.49 (1.28%)
PTC 25.80 Increased By ▲ 2.35 (10.02%)
SEARL 103.60 Increased By ▲ 5.66 (5.78%)
TELE 8.30 Increased By ▲ 0.08 (0.97%)
TOMCL 35.00 Decreased By ▼ -0.03 (-0.09%)
TPLP 13.30 Decreased By ▼ -0.25 (-1.85%)
TREET 22.16 Decreased By ▼ -0.57 (-2.51%)
TRG 55.59 Increased By ▲ 2.72 (5.14%)
UNITY 32.97 Increased By ▲ 0.01 (0.03%)
WTL 1.60 Increased By ▲ 0.08 (5.26%)
BR100 11,727 Increased By 342.7 (3.01%)
BR30 36,377 Increased By 1165.1 (3.31%)
KSE100 109,513 Increased By 3238.2 (3.05%)
KSE30 34,513 Increased By 1160.1 (3.48%)
Pakistan Print 2019-12-18

ICI Pakistan strengthens its partnership with AstraZeneca

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZenec
Published 18 Dec, 2019 12:00am

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZeneca GCC Country President Ismail Shehada visited ICI Pakistan and met with key stakeholders during his two-day visit to renew the existing relationship and explore potential new avenues of partnership to alleviate suffering and build a platform for patients and caregivers to treat high burden of diseases in Pakistan.

Gracing the ceremony at the ICI Pakistan Head Office, Mike Nithavrianakis, British Deputy High Commissioner Karachi and Trade Director for Pakistan, emphasised the importance of building a sustainable ecosystem to provide much needed care to patients in Pakistan.

Speaking on the occasion, ICI Pakistan Chief Executive Asif Jooma said, "ICI Pakistan has been in the pharmaceuticals business since 1993 and seeks to further enhance its global partnerships and introduce innovative products."

Shehada added, "AstraZeneca has an interest in the region and intends to grow its business through providing improved solutions for patients." He further stated, "AstraZeneca is a full healthcare company providing not only innovative molecules but which believes in going beyond medication alone by looking to introduce customised solutions to meet local needs and requirements."-PR

Copyright Business Recorder, 2019

Comments

Comments are closed.